519 related articles for article (PubMed ID: 30635033)
1. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA; Budde K; Halloran PF; Doberer K; Rostaing L; Eskandary F; Christamentl A; Wahrmann M; Regele H; Schranz S; Ely S; Firbas C; Schörgenhofer C; Kainz A; Loupy A; Härtle S; Boxhammer R; Jilma B; Böhmig GA
Trials; 2022 Apr; 23(1):270. PubMed ID: 35395951
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K; Duerr M; Halloran PF; Eskandary F; Budde K; Regele H; Reeve J; Borski A; Kozakowski N; Reindl-Schwaighofer R; Waiser J; Lachmann N; Schranz S; Firbas C; Mühlbacher J; Gelbenegger G; Perkmann T; Wahrmann M; Kainz A; Ristl R; Halleck F; Bond G; Chong E; Jilma B; Böhmig GA
J Am Soc Nephrol; 2021 Mar; 32(3):708-722. PubMed ID: 33443079
[TBL] [Abstract][Full Text] [Related]
5. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
[TBL] [Abstract][Full Text] [Related]
6. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic challenge of late antibody-mediated kidney allograft rejection.
Böhmig GA; Eskandary F; Doberer K; Halloran PF
Transpl Int; 2019 Aug; 32(8):775-788. PubMed ID: 30955215
[TBL] [Abstract][Full Text] [Related]
10. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.
Mühlbacher J; Schörgenhofer C; Doberer K; Dürr M; Budde K; Eskandary F; Mayer KA; Schranz S; Ely S; Reiter B; Chong E; Adler SH; Jilma B; Böhmig GA
Transpl Int; 2021 Aug; 34(8):1542-1552. PubMed ID: 34153143
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
Streichart L; Felldin M; Ekberg J; Mjörnstedt L; Lindnér P; Lennerling A; Bröcker V; Mölne J; Holgersson J; Daenen K; Wennberg L; Lorant T; Baid-Agrawal S
Trials; 2024 Mar; 25(1):213. PubMed ID: 38519988
[TBL] [Abstract][Full Text] [Related]
13. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
Vo AA; Choi J; Kim I; Louie S; Cisneros K; Kahwaji J; Toyoda M; Ge S; Haas M; Puliyanda D; Reinsmoen N; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Nov; 99(11):2356-63. PubMed ID: 26018350
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
16. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.
Pongpirul W; Chancharoenthana W; Pongpirul K; Leelahavanichkul A; Kittikowit W; Jutivorakool K; Nonthasoot B; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K; Townamchai N
Nephrology (Carlton); 2018 Feb; 23(2):169-174. PubMed ID: 27888573
[TBL] [Abstract][Full Text] [Related]
17. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
18. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
[TBL] [Abstract][Full Text] [Related]
19. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.
Vo AA; Huang E; Ammerman N; Toyoda M; Ge S; Haas M; Zhang X; Peng A; Najjar R; Williamson S; Myers C; Sethi S; Lim K; Choi J; Gillespie M; Tang J; Jordan SC
Am J Transplant; 2022 Apr; 22(4):1133-1144. PubMed ID: 34910841
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
